Literature DB >> 10729226

Identification and characterization of novel genes located at the t(1;15)(p36.2;q24) translocation breakpoint in the neuroblastoma cell line NGP.

L C Amler1, A Bauer, R Corvi, S Dihlmann, C Praml, W K Cavenee, M Schwab, G M Hampton.   

Abstract

The distal portion of chromosome 1p is frequently deleted in several human cancers, suggesting the presence of one or more putative tumor suppressor genes on this chromosomal arm. In human neuroblastoma, a consistently deleted region at 1p36.1-p36.2 has been defined by comparison of molecular loss of heterozygosity (LOH) analyses. Recently we described the identification of a yeast artificial chromosome, YAC 927G4, that spans a translocation/duplication breakpoint within the minimally defined LOH region at 1p36.1-p36.2 in the neuroblastoma cell line NGP. Here we describe the identification of two overlapping P1 artificial chromosomes comprising 220 kb at the distal end of YAC 927G4, which we have used as hybridization probes under modified conditions to screen a composite, normalized cDNA library (IMAGE cDNA library). Hybridization screening resulted in the rapid and comprehensive identification of partial cDNAs of which a portion comprised two novel candidate genes, termed DNB1/ARPh and DNB5, which encode putative proteins of 1011 and 447 amino acids, respectively. The DNB1/ARPh gene, which was found to be ubiquitously expressed in human adult and fetal tissues, is highly related to the DRPLA gene, in which expansion of a CAG triplet appears to be causal in the dentatorubral and pallidolysian atrophy disease phenotype. The DNB5 sequence, in contrast, which is predominantly expressed in brain tissues and fetal kidney, failed to show any similarity to sequences in the public domain. A preliminary assessment of transcription and sequence of both genes in several neuroblastoma cell lines does not, thus far, support a causal role in neuroblastoma. However, further analyses are required to confirm these results. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729226     DOI: 10.1006/geno.1999.6097

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  9 in total

1.  Fetal neuroblastoma: ultrasonography and magnetic resonance imaging findings in the prenatal and postnatal IV-S stage.

Authors:  Heron Werner; Pedro Daltro; Taisa Davaus; Edward Araujo Júnior
Journal:  Obstet Gynecol Sci       Date:  2016-09-13

2.  Dysfunction of the Cerebral Glucose Transporter SLC45A1 in Individuals with Intellectual Disability and Epilepsy.

Authors:  Myriam Srour; Noriaki Shimokawa; Fadi F Hamdan; Christina Nassif; Chantal Poulin; Lihadh Al Gazali; Jill A Rosenfeld; Noriyuki Koibuchi; Guy A Rouleau; Aisha Al Shamsi; Jacques L Michaud
Journal:  Am J Hum Genet       Date:  2017-04-20       Impact factor: 11.025

3.  A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.

Authors:  Kristina A Cole; Edward F Attiyeh; Yael P Mosse; Michael J Laquaglia; Sharon J Diskin; Garrett M Brodeur; John M Maris
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

4.  miR-32 and its target SLC45A3 regulate the lipid metabolism of oligodendrocytes and myelin.

Authors:  D Shin; S Y B Howng; L J Ptáček; Y-H Fu
Journal:  Neuroscience       Date:  2012-04-17       Impact factor: 3.590

5.  Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

Authors:  Lam C Tsoi; Sarah L Spain; Jo Knight; Eva Ellinghaus; Philip E Stuart; Francesca Capon; Jun Ding; Yanming Li; Trilokraj Tejasvi; Johann E Gudjonsson; Hyun M Kang; Michael H Allen; Ross McManus; Giuseppe Novelli; Lena Samuelsson; Joost Schalkwijk; Mona Ståhle; A David Burden; Catherine H Smith; Michael J Cork; Xavier Estivill; Anne M Bowcock; Gerald G Krueger; Wolfgang Weger; Jane Worthington; Rachid Tazi-Ahnini; Frank O Nestle; Adrian Hayday; Per Hoffmann; Juliane Winkelmann; Cisca Wijmenga; Cordelia Langford; Sarah Edkins; Robert Andrews; Hannah Blackburn; Amy Strange; Gavin Band; Richard D Pearson; Damjan Vukcevic; Chris C A Spencer; Panos Deloukas; Ulrich Mrowietz; Stefan Schreiber; Stephan Weidinger; Sulev Koks; Külli Kingo; Tonu Esko; Andres Metspalu; Henry W Lim; John J Voorhees; Michael Weichenthal; H Erich Wichmann; Vinod Chandran; Cheryl F Rosen; Proton Rahman; Dafna D Gladman; Christopher E M Griffiths; Andre Reis; Juha Kere; Rajan P Nair; Andre Franke; Jonathan N W N Barker; Goncalo R Abecasis; James T Elder; Richard C Trembath
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330

Review 6.  Atrophin proteins: an overview of a new class of nuclear receptor corepressors.

Authors:  Lei Wang; Chih-Cheng Tsai
Journal:  Nucl Recept Signal       Date:  2008-10-31

7.  Connecting myelin-related and synaptic dysfunction in schizophrenia with SNP-rich gene expression hubs.

Authors:  Hedi Hegyi
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

8.  Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.

Authors:  Jaap Kool; Anthony G Uren; Carla P Martins; Daoud Sie; Jeroen de Ridder; Geoffrey Turner; Miranda van Uitert; Konstantin Matentzoglu; Wendy Lagcher; Paul Krimpenfort; Jules Gadiot; Colin Pritchard; Jack Lenz; Anders H Lund; Jos Jonkers; Jane Rogers; David J Adams; Lodewyk Wessels; Anton Berns; Maarten van Lohuizen
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

9.  A genome-wide scan for breast cancer risk haplotypes among African American women.

Authors:  Chi Song; Gary K Chen; Robert C Millikan; Christine B Ambrosone; Esther M John; Leslie Bernstein; Wei Zheng; Jennifer J Hu; Regina G Ziegler; Sarah Nyante; Elisa V Bandera; Sue A Ingles; Michael F Press; Sandra L Deming; Jorge L Rodriguez-Gil; Stephen J Chanock; Peggy Wan; Xin Sheng; Loreall C Pooler; David J Van Den Berg; Loic Le Marchand; Laurence N Kolonel; Brian E Henderson; Chris A Haiman; Daniel O Stram
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.